Long-Term Safety, Tolerability, And Efficacy of Efgartigimod in Patients with Generalized Myasthenia Gravis: Concluding Analyses from the ADAPT+ Study

A Phase 3, Open-Label, Multicenter Study To Evaluate Eculizumab In Adolescents With Refractory Generalized Myasthenia Gravis

Author:Brandsema, John F.   Ginsberg, Matthew   Hoshino, Hideki   Mimaki, Masakazu   Nagata, Satoru   Rao, Vamshi   Ruzhansky, Katherine   Suresh, Niraja   Tiongson, Emmanuelle   Yamanouchi, Hideo   Frick, Glen   Hicks, Eden   Liao, Serena   Howard, James   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.009  

Author Institution:Division of Neurology, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA, Philadelphia, PA  Department of Neurology, Akron Children’s Hospital, Akron, OH, USA, Akron, OH  Department of Pediatrics, Teikyo University School of Medicine, Tokyo, Japan, Tokyo, Japan  Department of Pediatrics, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, Tokyo, Japan  Division of Neurology, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL  Department of Neurology, Medical University of South Carolina, Charleston, SC, USA, Charleston, SC  University of South Florida Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL  Division of Neurology, Children’s Hospital Los Angeles, Los Angeles, CA, USA, Los Angeles, CA  Department of Pediatrics, Saitama Medical University, Saitama, Japan, Saitama, Japan  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Voorhees, NJ  Department of Neurology, The University of North Carolina, Chapel Hill, NC, USA, Chapel Hill, NC  

CD11c+ B cells Are Fundamentally Altered in Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis